Form 4: Myriad Genetics Director Receives Equity Grant

Director S. Louise Phanstiel was granted 59,701 restricted stock units in Myriad Genetics, Inc.

Summary

• Director S. Louise Phanstiel acquired 59,701 restricted stock units (RSUs) on June 4, 2026.
• The grant was issued under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock.
• The total beneficial ownership for the director following this transaction is 341,652 shares.
• The RSUs vest on the earlier of the first anniversary of the grant or the date of the next annual stockholders meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Director alignment with shareholder interests through increased equity ownership.

Negatives

• None identified.

Risks

• Vesting is subject to the terms of the 2026 Equity Incentive Plan.

Future Outlook

The RSUs are expected to vest within one year, either on the first anniversary of the grant or at the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to align board member incentives with long-term shareholder value creation in the biotechnology sector.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for mid-cap biotechnology firms.
• The vesting schedule aligns with typical one-year cliff vesting cycles observed in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact, reflects standard director compensation.

Next Steps

• Vesting of the 59,701 RSUs on the earlier of June 4, 2027, or the next annual stockholders meeting.

Key Dates

Keywords

Myriad Genetics, MYGN, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation